CA209143: A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)

8912-CTO
Cancer - Brain
Principal Investigator: Tommy Mikkelsen, MD

The purposes of the study are to understand the

  1. Safety and tolerability of Nivolumab and Nivolumab in combination with Ipilimumab in a safety lead-in phase (Cohort 1, 1b) and
  2. The safety, tolerability and efficacy of Nivolumab versus Bevacizumab (Cohort 2) in patients diagnosed with recurrent glioblastoma (GBM)
  • Subjects with histologically confirmed Grade IV malignant glioma
  • Previous treatment with radiotherapy and temozolomide
  • Documented first recurrence of GBM
  • Karnofsky performance status (PS) = 70

Please contact us for a full list of eligibility requirements.

Open
Tiffany Pearce
(313) 916-1784